ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIA

Bruno Speck, Mortimer M. Bortin, Richard Champlin, John M. Goldman, Roger H. Herzig, Philip B. Mcglave, Hans A. Messner, Roy S. Weiner, Alfred A. Rimm

Research output: Contribution to journalArticlepeer-review

192 Scopus citations

Abstract

In 117 patients with chronic myelogenous leukaemia (CML) treatment with a combination of high-dose chemoradiotherapy plus transplantation of allogeneic bone-marrow from HLA-identical, mixed-lymphocyte-culture-identical siblings resulted in an actuarial probability of 3-year survival of 63±16% (95% confidence interval) for 39 patients transplanted in chronic phase; 36±14% for 56 transplanted in accelerated phase; and 12±15% for 22 transplanted during blast crisis. Irrespective of disease status at the time of transplantation, and in contrast to chemotherapy, a plateau-effect was observed in the survival curves starting 14 to 19 months after transplantation. The actuarial probability of recurrent or persistent leukaemia at 3 years was 7±9% for patients transplanted in chronic phase, 41+19% for accelerated phase, and 41±39% for blastic phase. All relapses occurred within 18 months of transplantation. This study demonstrates that long-term disease-free survival in CML can be achieved with bone-marrow transplantation. Best results were obtained in patients transplanted during chronic phase of the disease.

Original languageEnglish (US)
Pages (from-to)665-668
Number of pages4
JournalThe Lancet
Volume323
Issue number8378
DOIs
StatePublished - Mar 24 1984

Fingerprint Dive into the research topics of 'ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIA'. Together they form a unique fingerprint.

Cite this